Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201

CONCLUSIONS: Our studies reveal a therapeutic vulnerability of DIPG cells through targeting the SUV39H1-H3K9me3 pathway and compensatory signaling loops for treating this devastating disease. Combining SUV39H1-targeting chaetocin with other agents such as ONC201 may offer a new strategy for effective DIPG treatment.PMID:38011799 | DOI:10.1093/neuonc/noad222

Source: Ann Oncol - November 27, 2023 Category: Cancer & Oncology Authors: Dazhuan Eric Xin Yunfei Liao Rohit Rao Sean Ogurek Soma Sengupta Mei Xin William L Seibel Richard T Graham Carl Koschmann Q Richard Lu Source Type: research